Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding A Randomized Trial

被引:136
|
作者
Sung, Joseph J. Y.
Barkun, Alan
Kuipers, Ernst J.
Mossner, Joachim
Jensen, Dennis M.
Stuart, Robert
Lau, James Y.
Ahlbom, Henrik
Kilhamn, Jan
Lind, Tore
机构
[1] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China
[2] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[3] Erasmus MC Univ, Med Ctr, Rotterdam, Netherlands
[4] Univ Leipzig, Med Klin & Poliklin 2, Leipzig, Germany
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Digest Dis Res Ctr, Ctr Ulcer Res & Educ, Los Angeles, CA USA
[7] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland
[8] AstraZeneca Res & Dev, Molndal, Sweden
关键词
PUMP INHIBITOR THERAPY; PLACEBO-CONTROLLED MULTICENTER; ENDOSCOPIC TREATMENT; COCHRANE-COLLABORATION; CONTINUOUS-INFUSION; ACID SUPPRESSION; INTRAGASTRIC PH; METAANALYSIS; OMEPRAZOLE; COAGULATION;
D O I
10.7326/0003-4819-150-7-200904070-00105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Use of proton-pump inhibitors in the management of peptic ulcer bleeding is controversial because discrepant results have been reported in different ethnic groups. Objective: To determine whether intravenous esomeprazole prevents recurrent peptic ulcer bleeding better than placebo in a multi-ethnic patient sample. Design: Randomized trial conducted between October 2005 and December 2007; patients, providers, and researchers were blinded to group assignment. Setting: 91 hospital emergency departments in 16 countries. Patients: Patients 18 years or older with peptic ulcer bleeding from a single gastric or duodenal ulcer showing high-risk stigmata. Intervention: Intravenous esomeprazole bolus, 80 mg, followed by 8-mg/h infusion, over 72 hours or matching placebo, each given after successful endoscopic hemostasis. Intervention was allocated by computer-generated randomization. After infusion, both groups received oral esomeprazole, 40 mg/d, for 27 days. Measurements: The primary end point was rate of clinically significant recurrent bleeding within 72 hours. Recurrent bleeding within 7 and 30 days, death, surgery, endoscopic re-treatment, blood transfusions, hospitalization, and safety were also assessed. Results: Of 767 patients randomly assigned, 764 provided data for an intention-to-treat analysis (375 esomeprazole recipients and 389 placebo recipients). Fewer patients receiving intravenous esomeprazole (22 of 375) had recurrent bleeding within 72 hours than those receiving placebo (40 of 389) (5.9% vs. 10.3%; difference, 4.4 percentage points [95% Cl, 0.6% to 8.3%]; P = 0.026). The difference in bleeding recurrence remained significant at 7 days and 30 days (P = 0.010). Esomeprazole also reduced endoscopic retreatment (6.4% vs. 11.6%; difference, 5.2 percentage points [95% Cl of difference, 1.1 percentage points to 9.2 percentage points]; P = 0.012), surgery (2.7% vs. 5.4%), and all-cause mortality rates (0.8% vs. 2.1%) more than placebo, although differences for the latter 2 comparisons were not significant. About 10% and 40% of patients in both groups reported serious and nonserious adverse events, respectively. Limitation: Endoscopic therapy was not completely standardized; some patients received epinephrine injection, thermal coagulation, or hemoclips alone, whereas others received combination therapy, but there were similar proportions with single therapy in each group. Conclusion: High-dose intravenous esomeprazole given after successful endoscopic therapy to patients with high-risk peptic ulcer bleeding reduced recurrent bleeding at 72 hours and had sustained clinical benefits for up to 30 days.
引用
收藏
页码:455 / +
页数:13
相关论文
共 50 条
  • [1] Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding
    Alan B. R. Thomson
    [J]. Current Gastroenterology Reports, 2009, 11 (5) : 339 - 341
  • [2] Intravenous Esomeprazole A Pharmacoeconomic Profile of its Use in the Prevention of Recurrent Peptic Ulcer Bleeding
    Keating, Gillian M.
    [J]. PHARMACOECONOMICS, 2011, 29 (06) : 535 - 543
  • [3] Intravenous Esomeprazole for Prevention of Peptic Ulcer Rebleeding: A Randomized Trial in Chinese Patients
    Yu Bai
    Dong-Feng Chen
    Rong-Quan Wang
    You-Xiang Chen
    Rui-Hua Shi
    De-An Tian
    Huifang Chen
    Stefan Eklund
    Zhao-Shen Li
    [J]. Advances in Therapy, 2015, 32 : 1160 - 1176
  • [4] Intravenous Esomeprazole for Prevention of Peptic Ulcer Rebleeding: A Randomized Trial in Chinese Patients
    Bai, Yu
    Chen, Dong-Feng
    Wang, Rong-Quan
    Chen, You-Xiang
    Shi, Rui-Hua
    Tian, De-An
    Chen, Huifang
    Eklund, Stefan
    Li, Zhao-Shen
    [J]. ADVANCES IN THERAPY, 2015, 32 (11) : 1160 - 1176
  • [5] Intravenous esomeprazole for prevention of peptic ulcer re-bleeding:: rationale/design of Peptic Ulcer Bleed study
    Sung, J. J. Y.
    Moessner, J.
    Barkun, A.
    Kuipers, E. J.
    Lau, J.
    Jensen, D.
    Stuart, R.
    Junghard, O.
    Olsson, G.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (08) : 666 - 677
  • [6] BLEEDING PEPTIC-ULCER - PREVENTION OF RECURRENT BLEEDING
    FRIEDRICHS, O
    [J]. LEBER MAGEN DARM, 1995, 25 (03) : 138 - 138
  • [7] Esomeprazole for the treatment of peptic ulcer bleeding
    den Hoed, Caroline M.
    Kuipers, Ernst J.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (06) : 679 - 695
  • [8] Intravenous EsomeprazoleA Pharmacoeconomic Profile of its Use in the Prevention of Recurrent Peptic Ulcer Bleeding
    Gillian M. Keating
    [J]. PharmacoEconomics, 2011, 29 : 535 - 543
  • [9] Effects of Intravenous and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy
    Sung, Joseph J.
    Suen, Bing-yee
    Ching, Jessica
    Chan, Francis K. L.
    Wu, Justin C.
    Chiu, Philip W.
    Lau, James Y.
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S192 - S193
  • [10] Cost Effectiveness of High-Dose Intravenous Esomeprazole for Peptic Ulcer Bleeding
    Barkun, Alan N.
    Adam, Viviane
    Sung, Joseph J. Y.
    Kuipers, Ernst J.
    Moessner, Joachim
    Jensen, Dennis
    Stuart, Robert
    Lau, James Y.
    Naucler, Emma
    Kilhamn, Jan
    Granstedt, Helena
    Liljas, Bengt
    Lind, Tore
    [J]. PHARMACOECONOMICS, 2010, 28 (03) : 217 - 230